The lack of antitumor effect of ZA in vivo on the NRAS mutant and BRAF mutant and PTEN null melanoma cells may be explained by the fact, that around 50–60% of ZA accumulates in the skeleton and the remaining part is excreted in the first 24hs after drug administration [66, 67]. Here, NRAS is linked to melanoma.